Nabi Biopharmaceuticals (NABI) Announces Results of NicVAX® Phase II Study in Combination With Varenicline
10/17/2012 9:37:10 AM
ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi today announced that Nabi's Board of Directors has set October 26, 2012 as the record date with respect to the cash dividend to be paid in connection with the proposed business combination transaction of Nabi Biopharmaceuticals (Nadsaq:NABI) and Biota Holdings Limited (ASX:BTA.AX). As previously disclosed, Nabi intends to return to its stockholders in the form of a dividend Nabi's remaining cash in excess of the $27 million required under the transaction agreement with Biota to be held by Nabi at the completion of the transaction, after satisfying outstanding liabilities.
comments powered by